Opinions
David Driscoll
Novozymes A/S ADR
NVZMY-PK
BUY
Dec 19, 2023
N/A
Stock price when the opinion was issued
0
It's the ideal tool to help you make quicker, more informed decisions for
managing and tracking your investments.
You might be interested:
BUY ON WEAKNESS
This is an industrial enzymes company, spun out of Novo Nordisk. It has been a solid performer with a good balance sheet. The problem is that there are rarely good buying opportunities. It trades at a high earnings multiple and rarely misses earnings estimates, for example. This would be a good company to buy in a recession.
HOLD
Are merging with another Danish company which will remake the company because it gets them into the biologics industry. The street didn't like the price they were paying at first, but the deal offers growth. Shares have been growing and will continue to do. Their dividend growth averages 10%. He's adding shares.